Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects

NCT03089333 is registered in ClinicalTrials.gov with University of Campinas, Brazil as lead sponsor.

NCT NCT03089333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03089333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects
Lead sponsor
University of Campinas, Brazil
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2016
Completion date
December 31, 2017
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blood pressure, cardiac hypertrophy, diabetes mellitus, type 2, hypertension, microalbuminuria, obesity, vascular stiffness